siRNA基因治疗在肌腱损伤修复中的研究进展

doi:10.19586/j.2095-2341.2024.0196

生物技术进展 ›› 2025, Vol. 15 ›› Issue (3): 411-417.DOI: 10.19586/j.2095-2341.2024.0196

siRNA基因治疗在肌腱损伤修复中的研究进展

邱冰月¹(), 施家腾¹(), 金静²

^1.苏州市吴江区第五人民医院急诊重症监护医学系，江苏苏州 215000
^2.浙江省人民医院康复医学系，杭州 310000

收稿日期:2024-12-11 接受日期:2025-02-27 出版日期:2025-05-25 发布日期:2025-07-01
通讯作者: 施家腾
作者简介:邱冰月 E-mail: 1147490870@qq.com；

Research Progress of siRNA Gene Therapy in Tendon Injury Repair

Bingyue QIU¹(), Jiateng SHI¹(), Jing JIN²

^1.Department of Emergency Intensive Care Medicine，Suzhou Wujiang District Fifth People's Hospital，Jiangsu Suzhou 215000，China
^2.Rehabilitation Medicine，Zhejiang Provincial People's Hospital，Hangzhou 310000，China

Received:2024-12-11 Accepted:2025-02-27 Online:2025-05-25 Published:2025-07-01
Contact: Jiateng SHI

摘要/Abstract

摘要：

肌腱损伤是创伤外科的常见病症之一，临床上主要采用手术缝合方式进行治疗，但是术后存在再次断裂和粘连形成的风险。近些年多款基于RNA干扰（RNA interference，RNAi）的核酸药物上市，基因治疗受到广泛关注。然而，由于小干扰RNA（small interfering RNA，siRNA）药物易降解，体内存在核酸内切酶问题，载体的选择至关重要。相较于易导致突变的病毒载体，纳米载体具备更高的生物安全性和可修饰性。系统总结了siRNA的作用机制、基因治疗载体的优化策略及其在肌腱修复中的应用进展，并展望了纳米载体在临床转化中的潜力，以期为肌腱损伤的治疗提供参考。

关键词: RNA干扰, 小干扰RNA, 基因治疗, 肌腱修复, 纳米颗粒

Abstract:

Tendon injury is one of the most common symptoms in trauma surgery， which is mainly treated by surgical suturing in clinic. However， surgical treatment remains complications of re-reputure and adhesion formation after operation. In recent years， multiple nucleic acid drugs based on RNA interference （RNAi） have been on the market and gene therapy has received widespread attention. It is critical to choose a kind of suitable carrier to avoid the degradation of small interfering RNA （siRNA） and escape the endonucleases. Compared to the viral vectors that are prone to mutations， nanoparticles have higher safety and modifiability. This review systematically summarized the mechanism of action of siRNA， optimization strategies for gene therapy vectors， and their application progress in tendon repair， and looks forward to the potential of nanocarriers in clinical translation.

Key words: RNA interference, siRNA, gene therapy, tendon repair, nanoparticle

中图分类号:

Q789

邱冰月, 施家腾, 金静. siRNA基因治疗在肌腱损伤修复中的研究进展[J]. 生物技术进展, 2025, 15(3): 411-417.

Bingyue QIU, Jiateng SHI, Jing JIN. Research Progress of siRNA Gene Therapy in Tendon Injury Repair[J]. Current Biotechnology, 2025, 15(3): 411-417.

参考文献 36

1	VOLETI P B, BUCKLEY M R, SOSLOWSKY L J. Tendon healing: repair and regeneration[J]. Annu. Rev. Biomed. Eng., 2012, 14: 47-71.
2	MILLAR N L, SILBERNAGEL K G, THORBORG K, et al.. Tendinopathy[J/OL]. Nat. Rev. Dis. Primers, 2021, 7: 1[2025-04-08]. .
3	TANG J B. Flexor tendon injuries[J]. Clin. Plast. Surg., 2019, 46(3): 295-306.
4	TANG J B, ZHOU Y L, WU Y F, et al.. Gene therapy strategies to improve strength and quality of flexor tendon healing[J]. Expert Opin. Biol. Ther., 2016, 16(3): 291-301.
5	YIN H, KANASTY R L, ELTOUKHY A A, et al.. Non-viral vectors for gene-based therapy[J]. Nat. Rev. Genet., 2014, 15(8): 541-555.
6	PÉREZ-CARRIÓN M D, POSADAS I, CEÑA V. Nanoparticles and siRNA: a new era in therapeutics?[J/OL]. Pharmacol. Res., 2024, 201: 107102[2025-04-08]. .
7	DONG Y, SIEGWART D J, ANDERSON D G. Strategies, design, and chemistry in siRNA delivery systems[J]. Adv. Drug Deliv. Rev., 2019, 144: 133-147.
8	ALSHAER W, ZUREIGAT H, KARAKI A A L, et al.. siRNA: mechanism of action, challenges, and therapeutic approaches[J/OL]. Eur. J. Pharmacol., 2021, 905: 174178[2025-04-08]. .
9	KARA G, CALIN G A, OZPOLAT B. RNAi-based therapeutics and tumor targeted delivery in cancer[J/OL]. Adv. Drug Deliv. Rev., 2022, 182: 114113[2025-04-08]. .
10	ZHANG M M, BAHAL R, RASMUSSEN T P, et al.. The growth of siRNA-based therapeutics: updated clinical studies[J/OL]. Biochem. Pharmacol., 2021, 189: 114432[2025-04-08]. .
11	PAUNOVSKA K, LOUGHREY D, DAHLMAN J E. Drug delivery systems for RNA therapeutics[J]. Nat. Rev. Genet., 2022, 23(5): 265-280.
12	LI X, LE Y, ZHANG Z, et al.. Viral vector-based gene therapy[J/OL]. Int. J. Mol. Sci., 2023, 24(9): 7736[2025-04-08]. .
13	LIN L, CHEN L, WANG H, et al.. Adenovirus-mediated transfer of siRNA against Runx2/Cbfa1 inhibits the formation of heterotopic ossification in animal model[J]. Biochem. Biophys. Res. Commun., 2006, 349(2): 564-572.
14	RUAN H, LIU S, LI F, et al.. Prevention of tendon adhesions by ERK2 small interfering RNAs[J]. Int. J. Mol. Sci., 2013, 14(2): 4361-4371.
15	CHEN L, LIU J, TAO X, et al.. The role of Pin1 protein in aging of human tendon stem/progenitor cells[J]. Biochem. Biophys. Res. Commun., 2015, 464(2): 487-492.
16	HALD ALBERTSEN C, KULKARNI J A, WITZIGMANN D, et al.. The role of lipid components in lipid nanoparticles for vaccines and gene therapy[J/OL]. Adv. Drug Deliv. Rev., 2022, 188: 114416[2025-04-08]. .
17	JUNG H N, LEE S Y, LEE S, et al.. Lipid nanoparticles for delivery of RNA therapeutics: current status and the role of in vivo imaging[J]. Theranostics, 2022, 12(17): 7509-7531.
18	JAMIL S, MOUSAVIZADEH R, ROSHAN-MONIRI M, et al.. Angiopoietin-like 4 enhances the proliferation and migration of tendon fibroblasts[J]. Med. Sci. Sports Exerc., 2017, 49(9): 1769-1777.
19	SHUKUNAMI C, TAKIMOTO A, NISHIZAKI Y, et al.. Scleraxis is a transcriptional activator that regulates the expression of tenomodulin, a marker of mature tenocytes and ligamentocytes[J/OL]. Sci. Rep., 2018, 8(1): 3155[2025-04-08]. .
20	NAKAHARA H, HASEGAWA A, OTABE K, et al.. Transcription factor mohawk and the pathogenesis of human anterior cruciate ligament degradation[J]. Arthritis Rheum., 2013, 65(8): 2081-2089.
21	XUE T, MAO Z, LIN L, et al.. Non-virus-mediated transfer of siRNAs against Runx2 and Smad4 inhibit heterotopic ossification in rats[J]. Gene Ther., 2010, 17(3): 370-379.
22	LU P, ZHANG G R, SONG X H, et al.. ColV siRNA engineered tenocytes for tendon tissue engineering[J/OL]. PLoS ONE, 2011, 6(6): e21154[2025-04-08]. .
23	CUI Q, FU S, LI Z. Hepatocyte growth factor inhibits TGF-β1-induced myofibroblast differentiation in tendon fibroblasts: role of AMPK signaling pathway[J]. J. Physiol. Sci., 2013, 63(3): 163-170.
24	CHEN S, JIANG S, ZHENG W, et al.. RelA/p65 inhibition prevents tendon adhesion by modulating inflammation, cell proliferation, and apoptosis[J/OL]. Cell Death Dis., 2017, 8(3): e2710[2025-04-08]. .
25	HUCKABY J T, LAI S K. PEGylation for enhancing nanoparticle diffusion in mucus[J]. Adv. Drug Deliv. Rev., 2018, 124: 125-139.
26	ARAMI S, RASHIDI M R, MAHDAVI M, et al.. Synthesis and characterization of Fe₃O₄-PEG-LAC-chitosan-PEI nanoparticle as a survivin siRNA delivery system[J]. Hum. Exp. Toxicol., 2017, 36(3): 227-237.
27	HLIL A R, THOMAS J, GARCIA-PUENTE Y, et al.. Structural and optical properties of Nd: YAB-nanoparticle-doped PDMS elastomers for random lasers[J/OL]. Sci. Rep., 2021, 11(1): 16803[2025-04-09]. .
28	CAI C, ZHANG X, LI Y, et al.. Self-healing hydrogel embodied with macrophage-regulation and responsive-gene-silencing properties for synergistic prevention of peritendinous adhesion[J/OL]. Adv. Mater., 2022, 34(5): e2106564[2025-04-09]. .
29	ZHOU Y L, YANG Q Q, YAN Y Y, et al.. Localized delivery of miRNAs targets cyclooxygenases and reduces flexor tendon adhesions[J]. Acta Biomater., 2018, 70: 237-248.
30	YANG Q Q, ZHANG L, ZHOU Y L, et al.. Morphological changes of macrophages and their potential contribution to tendon healing[J/OL]. Colloids Surf. B Biointerfaces, 2022, 209(Pt 1): 112145[2025-04-09]. .
31	SUN J, JU F, JIN J, et al.. M2 macrophage membrane-mediated biomimetic-nanoparticle carrying COX-siRNA targeted delivery for prevention of tendon adhesions by inhibiting inflammation[J/OL]. Small, 2023, 19(33): e2300326[2025-04-09]. .
32	WANG Y, MALCOLM D W, BENOIT D S W. Controlled and sustained delivery of siRNA/NPs from hydrogels expedites bone fracture healing[J]. Biomaterials, 2017, 139: 127-138.
33	FREEBERG M A T, FARHAT Y M, EASA A, et al.. Serpine1 knockdown enhances MMP activity after flexor tendon injury in mice: implications for adhesions therapy[J/OL]. Sci. Rep., 2018, 8(1): 5810[2025-04-09]. .
34	LIAO X, FALCON N D, MOHAMMED A A, et al.. Synthesis and formulation of four-arm PolyDMAEA-siRNA polyplex for transient downregulation of collagen type Ⅲ gene expression in TGF-β1 stimulated tenocyte culture[J]. ACS Omega, 2020, 5(3): 1496-1505.
35	王飞,严辰玥,孙嘉,等.siRNA非病毒载体递送用于肿瘤治疗的研究进展[J].北京生物医学工程,2023,42(5):541-545.
	WANG F, YAN C Y, SUN J, et al.. Research progress of non-viral delivery of siRNA for tumor therapy[J]. Beijing Biomed. Eng., 2023, 42(5): 541-545.
36	赵轩,任丽梅,王晓茹,等.siRNA靶向干扰TRAF6的表达对肺癌细胞增殖与凋亡的影响[J].生物技术进展,2024,14(5):875-881.
	ZHAO X, REN L M, WANG X R, et al.. Effects of siRNA targeting to interfere with the expression of TRAF6 on the proliferation and apoptosis of lung cancer cells[J]. Curr. Biotechnol., 2024, 14(5): 875-881.

[1]	李仪扬, 周执政, 王淑菲, 刘博雅, 刘宇飞, 李孝彦, 隋宏书, 刘东巍. CRISPR/Cas9基因编辑技术在疾病治疗中的应用与展望[J]. 生物技术进展, 2025, 15(1): 35-42.
[2]	王泓恺, 王俞杰, 赵潇涵, 荆钰含, 唐嘉毅, 隋宏书. 囊性纤维化基因治疗研究进展[J]. 生物技术进展, 2024, 14(5): 813-819.
[3]	李书翔, 安丽萍, 梁德娟, 王凯旋, 赵建国. 朊病毒病治疗方法的研究进展[J]. 生物技术进展, 2022, 12(2): 229-235.
[4]	权春菊, 郑忠亮. CRISPR/Cas及其衍生编辑技术在基因治疗中的应用进展[J]. 生物技术进展, 2021, 11(4): 518-525.
[5]	魏珍珍,曾振,杜梦潭,刘兴健,张志芳,胡小元,李轶女,易咏竹. 融合铁蛋白的猪瘟病毒囊膜蛋白E2的表达及鉴定[J]. 生物技术进展, 2020, 10(4): 386-392.
[6]	刘彦均,陈志胜. 新RNA编辑技术CRISPR-Cas13[J]. 生物技术进展, 2019, 9(6): 571-578.
[7]	杜梦潭,刘兴健,胡小元,张志芳,李轶女. 腺相关病毒的生产方式及其在基因治疗中的应用[J]. 生物技术进展, 2019, 9(4): 326-331.
[8]	叶明强,邝哲师,赵祥杰,吴福泉,李庆荣,肖阳,罗国庆. 转基因RNAi技术在动物抗病毒育种中的应用[J]. 生物技术进展, 2012, 2(4): 249-254.
[9]	赵丽琴,席斌,彭华松. 腺相关病毒(AAV)载体研究进展[J]. 生物技术进展, 2012, 2(2): 110-115.

siRNA基因治疗在肌腱损伤修复中的研究进展

Research Progress of siRNA Gene Therapy in Tendon Injury Repair

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 36

相关文章 9

编辑推荐

Metrics

本文评价